Compare Enveric Biosciences Inc (ENVB) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Johnson Controls International PLC — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Johnson Controls International PLC trades at $139.7 (market cap $87.10B). The key difference: Johnson Controls International PLC is far larger — about 16372.2× Enveric Biosciences Inc's market cap, and Johnson Controls International PLC pays a 1.12% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | JCI | |
|---|---|---|
Market Cap | $5.32M | $87.10B |
Sector | Health | Industrials |
52-Week High | $17.40 | $148.21 |
52-Week Low | $1.28 | $103.24 |
Enterprise Value | $408.82K | $95.93B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
JCI trades at $139.67, down 3.84% on the day, with a bullish technical signal from moving averages and support at $140. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.32. Revenue for 2025 was $23.60B, net income $3.29B, and profit margin expanded to 13.94%. Analyst consensus is strongly bullish with a $158.29 price target and no sell ratings among 45 analysts. Recent news highlights innovation awards and dividend declarations.
JCI presents a favorable outlook with consistent earnings beats, strong analyst support, and exposure to growth areas like energy efficiency. Risks include high valuation multiples (P/E 43.66) and increasing debt-to-asset ratio (26.06% in 2025). The stock's proximity to the $140 support level offers a potential entry point, but macroeconomic headwinds and execution risks in competitive markets warrant caution for investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
